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In the past years, magnetic resonance
angiography (MRA) has been recog-
nised as a powerful tool in the evalu-
ation of vascular disease in a majori-
ty of anatomic territories. It may be
applied with or without contrast 
media depending on the area of in-
vestigation, on the physiological
properties of the interesting vessels,
and mainly on the dedicated clinical
question [1].
Native techniques are still advo-
cated for the evaluation of the intra-
cranial circulation and in some plac-
es for the detection of carotid artery
disease as well as for detection of
peripheral arterial pathologies, be-
cause in these anatomical areas mo-
tion of the vessels is limited to minor
pulsation. This allows for longer im-
aging periods, correlated with bene-
ficial higher resolution of the result-
ing images. In other vascular territo-
ries, vessels are affected by second-
ary motion such as breathing or peri-
stalsis, and related artefacts prevent
the application of longer-lasting
MRA measurements. Other inherent
problems of native techniques, such
as saturation effects in time-of-flight
(TOF) MRA and phase wrapping in
phase-contrast (PC) MRA, are well
known and further support the intro-
duction of contrast-media-enhanced
vascular studies.
In contrast-enhanced (CE) MRA,
the arterial first pass of an intrave-
nously applied bolus of contrast 
media must be coordinated with the
data acquisition. Meanwhile, this has
successfully been applied to all ma-
jor arterial pathologies and the tech-
nique is under permanent evolution.
Various studies on the direct compar-
ison of CE MRA to intra-arterial
digital subtraction angiography
(DSA) demonstrate the high poten-
tial of the lesser-invasive MR tech-
nique and its advantage concerning
the three-dimensional approach to
the vessel and the pathology. In con-
trast, insufficiencies in in-plane reso-
lution and post-processing artefacts
in 3D CE MRA have also been de-
scribed. The stability of the bolus
during the most sensitive part of the
data acquisition period, namely at
the acquisition of the central lines in
k-space, depends on a variety of fac-
tors [2, 3]; among these, the distribu-
tion of the CM bolus, the CM relaxi-
vity, and the local flow physiology
are the most important. In a routine
clinical setting, the investigator ad-
justs injection rate, timing and
amount of contrast media to the mea-
surement sequence in order to
achieve maximum shortening of T1
values explicitly within the investi-
gated vasculature [4]. Especially for
the diagnostic workup of peripheral
arterial occlusive disease of the low-
er extremities this problem increases
due to the length of the interesting
field of view. Several measurements
have to be added and the bolus ge-
ometry must be adjusted to the entire
diagnostic area [3, 4].
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Optimised conditions for the visu-
alisation of the lower limb arteries
could be provided by a stable and
long-lasting CM supply as by blood-
pool agents, because this enables
longer measuring times and thus
high resolution. But so far the en-
hancement of the superimposing
veins prevents the clinical use as
equilibrium CM.
Venous signal contamination of
the arterial display in first-pass MRA
not only occurs in normal subjects
but to a much stronger extent in arte-
riosclerotic patients. It is therefore
one of the most problematic handi-
caps for peripheral MRA. Faster data
acquisition for each of the investigat-
ed volumes is recommended at the
price of resolution or signal-to-noise
ratio (SNR). In order to compensate
for decreased SNR, CM with strong-
er relaxivity effects can be applied.
Various new contrast agents for
MRA are recently under develop-
ment driven by the clinical demand
for more intensive, more specific or
longer-lasting enhancement charac-
teristics. Most of these contrast
agents are based on gadolinium 
compounds chelated to complicated
molecules. Two papers published in
this issue of “European Radiology”
present the results of multicentric tri-
als on a new 1.0 M Gd preparation
[5, 6]. While the safety issues of the
new compound are thoroughly tested
in one study without regard to the
clinical value of the investigation,
the second paper focuses on the im-
plications of the new CM on periph-
eral MRA.
With its large safety profile, the
tested CM presents many similarities
to one of the most often applied
agents: 0.5 M Gd-DTPA which has
been in use for approximately
20 years with only a low rate of
complications [7]. In the multicentric
study presented here [5], the CM
was tested not only for possible side
effects but the drug also underwent a
more detailed safety evaluation than
in most comparable phase-III Gd tri-
als. Therein, effects on the renal
function were under special focus.
The detailed analysis of the excre-
tion mechanism and the nephrologi-
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cal effects demonstrated a broad re-
nal tolerance [8]. Moreover, the sta-
bility of the Gd compound as defined
by the low transmetallation effect on
serum zinc values was investigated.
The properties of gadobutrol 1 M
for peripheral CE MRA were dem-
onstrated with direct comparison
with intra-arterial DSA in the second
paper [6]. The aim of that study was
to identify the equity of either meth-
od for the diagnostic of peripheral
arterial occlusive disease. The op-
tions of an improved bolus geometry
for sufficient and selective arterial
contrast effect in the peripheral cir-
culation have previously been dis-
cussed and were recommended for
3D MRA [9].
Recent studies have addressed
the benefits of the higher-concen-
trated Gd chelate by direct com-
parison with a standard concentra-
tion of 0.5 M in volunteers [10]. 
Future prospective trials on patients
with peripheral arteriosclerotic 
disease are required to demonstrate
the positive effects in a clinical 
setting.
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